VIT Stock Overview
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Vitura Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.12 |
| 52 Week High | AU$0.60 |
| 52 Week Low | AU$0.092 |
| Beta | 0.16 |
| 1 Month Change | -36.11% |
| 3 Month Change | -53.06% |
| 1 Year Change | -67.61% |
| 3 Year Change | -8.00% |
| 5 Year Change | n/a |
| Change since IPO | -66.18% |
Recent News & Updates
The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25
Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Recent updates
The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Feb 25Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)
Dec 13Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet
Nov 21Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?
Nov 01Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Jul 18Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%
Sep 12If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity
Sep 05Shareholder Returns
| VIT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -28.1% | -3.3% | 0.4% |
| 1Y | -67.6% | 29.3% | 6.0% |
Return vs Industry: VIT underperformed the Australian Pharmaceuticals industry which returned 29.3% over the past year.
Return vs Market: VIT underperformed the Australian Market which returned 6% over the past year.
Price Volatility
| VIT volatility | |
|---|---|
| VIT Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: VIT's share price has been volatile over the past 3 months.
Volatility Over Time: VIT's weekly volatility has increased from 13% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Rodney Cocks | vitura.com.au |
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for medicinal cannabis; CDA Clinics, which provides medicinal cannabis consultations and prescription services; and Cannadoc, a medicinal cannabis clinic that offers telehealth consultations. It also offers psychedelics under the Cortexa brand; and plant-based medications, such as medium chain triglyceride oil and whole flower products under the Adaya brand name.
Vitura Health Limited Fundamentals Summary
| VIT fundamental statistics | |
|---|---|
| Market cap | AU$60.47m |
| Earnings (TTM) | AU$9.40m |
| Revenue (TTM) | AU$119.66m |
7.0x
P/E Ratio0.6x
P/S RatioIs VIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIT income statement (TTM) | |
|---|---|
| Revenue | AU$119.66m |
| Cost of Revenue | AU$81.81m |
| Gross Profit | AU$37.85m |
| Other Expenses | AU$28.45m |
| Earnings | AU$9.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.016 |
| Gross Margin | 31.63% |
| Net Profit Margin | 7.86% |
| Debt/Equity Ratio | 15.9% |
How did VIT perform over the long term?
See historical performance and comparison